<DOC>
	<DOCNO>NCT01621724</DOCNO>
	<brief_summary>WT1 TCR gene therapy new treatment acute myeloid leukaemia chronic myeloid leukaemia . Patient 's white blood cell ( T cell ) modify specifically fight leukaemia cell transfer gene T cell , allow recognize fragment protein call WT1 . This protein present surface leukaemia cell high level . The gene transfer T cell enables make new T cell receptor ( TCR ) , allow attack leukaemia cell high level WT1 surface . Using form gene therapy investigator convert patient 's immune system 's T cell T cell investigator hope much effective recognize kill leukaemia cell .</brief_summary>
	<brief_title>WT1 TCR Gene Therapy Leukaemia : A Phase I/II Safety Toxicity Study</brief_title>
	<detailed_description>This trial concern novel approach generate leukaemia antigen-specific T cell adoptive cellular therapy HLA-A*0201 patient acute myeloid leukaemia ( AML ) chronic myeloid leukaemia ( CML ) In study , patient T cell gene-modified use GMP grade retroviral vector contain gene WT1-specific , HLA-A2-restricted T cell receptor . This ex vivo gene therapy generate T cell express WT1-specific TCR thus able recognise WT1-expressing target cell . The autologous Cys1 WT1 TCR-transduced T cell re-infused back adult leukaemia patient follow lymphodepleting conditioning .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>General Age ≥ 18 year ≤ 75 year . Life expectancy ≥ 16 week ( 4 month ) . World Health Organisation ( WHO ) performance status 02 HLA A*0201 positive Completed previous course chemotherapy ≥ 4 week prior commence initial phase trial ( leucapheresis collection patient PBMC ) . Peripheral blood total lymphocyte count &gt; 0.5x109/L . Informed consent write ability cooperate treatment follow . Willing , able available collection PBMC/ T cell leucapheresis . Hepatitis B C , HTLV1 , Syphilis , HIV negative . Free serious concurrent illness . Female patient childbearing age must negative pregnancy test agree use reliable contraceptive method duration therapy 6 month afterwards . Male patient must agree use appropriate medically approve contraception trial six month afterwards . Haematological Biochemical Indices : Haemoglobin ( Hb ) ≥ 7.0 g/dl ; neutrophil ≥ 0.2 x 109/L ; total lymphocyte &gt; 0.5 x 109/L ; platelet ( Plts ) ≥ 40 x 109/L serum bilirubin , Alanine aminotransferase ( ALT ) and/or aspartate amino transferase ( AST ) &lt; 3 x upper normal limit calculate creatinine clearance ≥ 30 ml/min ( uncorrected value ) isotope clearance measurement ≥ 30ml/min Further disease specific inclusion criterion detail Protocol Age &lt; 18 year &gt; 75 year . Patients receive concurrent systemic corticosteroid whilst study . Within three month receive fludarabine ( time leucapheresis ) . Major thoracic and/or abdominal surgery precede three four week patient yet recover . Patients high medical risk nonmalignant systemic disease , well active uncontrolled infection . Patients condition , Investigator 's opinion would make patient good candidate clinical trial . Patients know serologically positive Hepatitis B , C , HTLV1 Syphilis HIV . Concurrent congestive heart failure prior history New York Heart Association ( NYHA ) class III/ IV cardiac disease Positive pregnancy test reluctance use contraception . Pregnant lactate woman exclude . History Severe Allergy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Gene therapy</keyword>
	<keyword>WT1 TCR</keyword>
	<keyword>AML</keyword>
	<keyword>CML</keyword>
</DOC>